Backed by Westlake, Oorja planning mid-stage study of IPF candidate: Venture Report

Westlake BioPartners is providing a $30 million series A round as the founding investor in newly unveiled Oorja, as the start-up prepares to start Phase II testing of a fibrosis treatment in which it sees first-in-class potential.

Based at the Texas Medical Center campus in Houston, Oorja Bio Inc. said FDA has cleared its IND for CD29 inhibitor ORJ-001 (formerly NP-201) to treat idiopathic pulmonary fibrosis. A Phase II study is set to begin this year...